ABOUT ASPEN

We have a proud heritage dating back more than 160 years and we are committed to sustaining life and promoting healthcare through increasing access to our high quality, affordable medicines and products.

With a market capitalisation of approximately US$10 billion, we are the largest pharmaceutical company listed on the JSE Limited (share code: APN) and we are ranked among the top 30 listed companies on this exchange.

SENS ANNOUNCEMENTS

INVESTOR CALENDAR

8 March 2018
Interim results announcement

9 March 2018
Interim results presentation in Cape Town

30 June 2018
Financial year end

13 September 2018
Year end results announcement, presentation and webcast at the JSE, Johannesburg

Click here for the 2017 results presentation

November 2018
Annual financial statements for 2018 year end published

6 December 2018
Annual General Meeting

LATEST RESULTS

Aspen Group Unaudited Interim Results for the six months ended 31 December 2017

Aspen interim results short form announcement

Aspen interim results presentation

Aspen interim results webcast

Regional
Overviews

SUB-SAHARAN AFRICA

DEVELOPED EUROPE

AUSTRALASIA

LATIN AMERICA

DEVELOPING EUROPE & CIS

Japan

China

Other Asia

Middle East and North Africa

USA & Canada

SUB-SAHARAN AFRICA

 

The SSA business provides a diverse basket of branded, generic, OTC and consumer health products which are supplied to both the private and public sectors primarily in South Africa. Our presence outside of South Africa is mainly in Namibia, Botswana, Tanzania, Kenya, Nigeria, Ghana and Uganda.

Key countries
Kenya
Namibia
Nigeria
South Africa
Tanzania
Products launched in 2017
30
(2016: 55)
 

IMS* value of pipeline as at 30 June 2017 anticipated to be launched in:
0 – 2 years
USD116 million


3 – 5 years
USD235 million

*South Africa only, rest of SSA not covered by IMS.

 

DEVELOPED EUROPE

 

Our Developed Europe business is made up of operations in Europe’s major developed countries. The Thrombosis portfolio makes up the largest proportion of regional revenue followed by the Anaesthetics portfolio. The API site at Oss, supported by its satellite operation at Sioux City, supplies APIs worldwide. The Notre Dame de Bondeville and Bad Oldesloe sites are strategically important manufacturers for the Group.

Key countries
France
Germany
Italy
The Netherlands
United Kingdom
Products launched in 2017
2
(2016: 9)
 

IMS value of pipeline as at 30 June 2017 anticipated to be launched in:
0 – 2 years
USD13 million


3 – 5 years
USD1 million

 

Australasia

 

We supply a diversified portfolio of branded prescription, OTC, consumer and infant nutritional products into Australia and New Zealand. We are one of the largest manufacturers in Australia and our manufacturing site in Melbourne produces certain tablets, liquids and semi-solids.

Key countries
Australia
New Zealand
Products launched in 2017
2
(2016: 9)
 

IMS value of pipeline as at 30 June 2017 anticipated to be launched in:
0 – 2 years
USD65 million


3 – 5 years
USD25 million

 

Latin America

 

We entered the Latin American market in 2008 and initially established a presence in Brazil, Mexico and Venezuela. We have expanded our coverage in this region and now also have a presence in Colombia, Chile, Ecuador, Costa Rica, Peru and Argentina and offer a comprehensive product range that encompasses branded, prescription and OTC products as well as infant nutritionals. We discontinued trade in Venezuela in the 2016 financial year. Our Vallejo site in Mexico has the capability to manufacture infant nutritionals as well as pharmaceutical solids, semi-solids and liquids.

Key countries
Argentina
Brazil
Chile
Colombia
Mexico
Products launched in 2017
3
(2016: 4)
 

IMS value of pipeline as at 30 June 2017 anticipated to be launched in:
0 – 2 years
USD423 million


3 – 5 years
USD290 million

 

Developing Europe & CIS

 

The main revenue contributor to our Developing Europe & CIS business is the Thrombosis Portfolio, followed by High Potency & Cytotoxic Brands. The newly acquired Anaesthetics portfolio currently contributes 12% to regional revenue and is expected to become more significant over time.

Key countries
Czech Republic
Poland
Romania
Russia
Slovakia
Products launched in 2017
Nil
(2016: nil)
 

IMS value of pipeline as at 30 June 2017 anticipated to be launched in:
0 – 2 years
USDnil


3 – 5 years
USD1 million

 

Japan

 

Aspen's subsidiary in Japan was officially opened in May 2015. Aspen Japan operates according to a flexible business model and employs innovative marketing activities to promote leading international pharmaceutical originator brands and authorised generics in Japan.

 
Number of products launched from pipeline
5
(2016: 7)
 

 
 

China

 

Aspen China was incorporated as wholly foreign-owned enterprise in July 2015 but has not been a significant contributor to the Group performance prior to the 2017 financial year. China is set to become a material contributor to Group revenue with a product range comprising the recently acquired thrombosis and anaesthetic brands as well as some smaller global brands.

 
Number of products launched from pipeline
Nil
(2016: n/a)
 

 
 

Other Asia

 

Other Asia comprises all Asian territories excluding China and Japan. Anaesthetics make up 36% of revenue in these countries, followed by several products in the Other Commercial Pharmaceutical Brands category. We have active trading subsidiaries in the Philippines, Taiwan and Malaysia.

Key countries and territories
Hong Kong
Indonesia
Philippines
Taiwan
Products launched in 2017
3
(2016: 8)
 

IMS value of pipeline as at 30 June 2017 anticipated to be launched in:
0 – 2 years
USD49 million


3 – 5 years
USD12 million

 

Middle East and North Africa

 

We supply globally branded pharmaceutical products as well as local brands into multiple territories within MENA. Egypt, Algeria and Saudi Arabia combined contributed approximately 50% to total sales in MENA for 2017 financial year.

Key countries
Algeria
Egypt
Morocco
Saudi Arabia
United Arab Emirates
Products launched in 2017
Nil
(2016: nil)
 

IMS value of pipeline as at 30 June 2017 anticipated to be launched in:
0 – 2 years
USD158 million


3 – 5 years
USD9 million

 

USA & Canada

 

Aspen Pharmacare Canada was founded in 2014 to support our products distributed in this region. The development of our complex API capabilities into niche FDF offerings represents an opportunity for future product launches in the United States. Our satellite API facility in Sioux City supports the Oss site in supplying APIs worldwide.

Key countries
Canada
USA
Products launched in 2017
Nil
(2016: 1)
 

IMS value of pipeline as at 30 June 2017 anticipated to be launched in:
0 – 2 years
USD97 million


3 – 5 years
USD1 671 million